Dementia and Alzheimer Disease

Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.

The 2 anti-Aβ monoclonal antibodies, in treatment for Alzheimer disease, are currently being tested in 2 phase III trials.

The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.

This guideline gives recommendations to improve diagnosis, health outcomes and care of individuals with prolonged disorders of consciousness.

The human recombinant monoclonal antibody is designed to increase progranulin levels to sustain neuron survival and moderate inflammation.

The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.

A new drug called BAN2401 has shown promise in decreasing amyloid in early AD, according to results from a phase II study.

The results conclude that treatment with crenezumab was associated with a consistent decrease in Aβ oligomer levels in the CSF.

The professor of age-related diseases and Dean of the University of Exeter Medical School provided insight into the safety and efficacy of pimavanserin studied in treatment for Alzheimer psychosis.

This technology offers a non-invasive, image-guided and reversible approach to blood-brain barrier, suggesting the possibility of its use in Alzheimer disease.

The senior lecturer in Clinical Pharmacy at Aston University spoke about the findings of the ZED study, which looked into the use of hypnotic z-drugs.

ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

BAN2401 produced a dose-dependent substantial reduction in brain amyloid plaque at the highest dose, resulting in subjects converting to amyloid negative.

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

A new study has found that an RNA-binding protein called TDP-43 could be a promising new biomarker for diagnosing amyotropic lateral sclerosis.

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

The FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.